Lyra Therapeutics, Inc. Fundamental Analysis (NASDAQ: LYRA)
Lyra Therapeutics, Inc. (NASDAQ: LYRA) shows moderate financial fundamentals with a PE ratio of -0.00, profit margin of -72.66%, and ROE of 12.11%. The company generates $0.0B in annual revenue with weak year-over-year growth of -74.05%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of -5457.5/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze LYRA's fundamental strength across five key dimensions:
Efficiency Score
WeakLYRA struggles to generate sufficient returns from assets.
Valuation Score
ExcellentLYRA trades at attractive valuation levels.
Growth Score
WeakLYRA faces weak or negative growth trends.
Financial Health Score
ExcellentLYRA maintains a strong and stable balance sheet.
Profitability Score
WeakLYRA struggles to sustain strong margins.
Key Financial Metrics
Is LYRA Expensive or Cheap?
P/E Ratio
LYRA trades at -0.00 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, LYRA's PEG of 0.00 indicates potential undervaluation.
Price to Book
The market values Lyra Therapeutics, Inc. at -0.05 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 0.52 times EBITDA. This is generally considered low.
How Well Does LYRA Make Money?
Net Profit Margin
For every $100 in sales, Lyra Therapeutics, Inc. keeps $-72.66 as profit after all expenses.
Operating Margin
Core operations generate -77.94 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $12.11 in profit for every $100 of shareholder equity.
ROA
Lyra Therapeutics, Inc. generates $-80.09 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Lyra Therapeutics, Inc. generates limited operating cash flow of $-3.30M, signaling weaker underlying cash strength.
Free Cash Flow
Lyra Therapeutics, Inc. generates weak or negative free cash flow of $-3.31M, restricting financial flexibility.
FCF Per Share
Each share generates $-1.87 in free cash annually.
FCF Yield
LYRA converts -459.86% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-0.00
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.00
vs 25 benchmark
P/B Ratio
Price to book value ratio
-0.05
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.16
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
-2.82
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.71
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
12.11
vs 25 benchmark
ROA
Return on assets percentage
-0.80
vs 25 benchmark
ROCE
Return on capital employed
-1.17
vs 25 benchmark
How LYRA Stacks Against Its Sector Peers
| Metric | LYRA Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -0.00 | 31.70 | Better (Cheaper) |
| ROE | 1211.14% | 448.00% | Excellent |
| Net Margin | -7266.08% | 22837.00% | Weak |
| Debt/Equity | -2.82 | 0.54 | Strong (Low Leverage) |
| Current Ratio | 1.71 | 5.63 | Neutral |
| ROA | -80.09% | -49.00% (disorted) | Weak |
LYRA outperforms its industry in 3 out of 6 key metrics, particularly excelling in ROE, but lagging in Net Margin.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Lyra Therapeutics, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
0.00%
Industry Style: Defensive, Growth, Innovation
DecliningEPS CAGR
28.10%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
24.91%
Industry Style: Defensive, Growth, Innovation
High Growth